Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Betta Pharmaceuticals Co., Ltd.
  6. Summary
    300558   CNE100002DD9

BETTA PHARMACEUTICALS CO., LTD.

(300558)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
47.28 44.61 45 44.94 44.18 Last
3371775 3586811 2217759 2040470 2932074 Volume
+4.49% -5.65% +0.87% -0.13% -1.69% Change
Estimated financial data (e)
Sales 2022 2 819 M 421 M 421 M
Net income 2022 442 M 65,9 M 65,9 M
Net cash position 2022 853 M 127 M 127 M
P/E ratio 2022 41,5x
Yield 2022 0,77%
Sales 2023 3 966 M 592 M 592 M
Net income 2023 725 M 108 M 108 M
Net cash position 2023 1 400 M 209 M 209 M
P/E ratio 2023 25,3x
Yield 2023 1,36%
Capitalization 18 352 M 2 739 M 2 739 M
EV / Sales 2022 6,21x
EV / Sales 2023 4,27x
Nbr of Employees 1 677
Free-Float 48,1%
More Financials
Company
Betta Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing, sales and marketing of drugs to treat malignant tumors, diabetes, cardiovascular and cerebrovascular diseases. The Company’s core product is icotinib, which is a kind of antineoplastic agent. Its products also include burn pain relieving plaster, oryzanol vitamin B1 and vitamin B6 tablets.... 
Read more
Sector
Pharmaceuticals
Calendar
08/25Earnings Release
More about the company
Ratings of Betta Pharmaceuticals Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about BETTA PHARMACEUTICALS CO., LTD.
05/23Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 202..
CI
05/04EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic E..
MT
04/29Betta Pharmaceuticals Co., Ltd. Approves 2021 Profit Distribution Plan
CI
04/26Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
04/25Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it has received CNY 30 million ..
CI
04/07Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021
CI
04/06Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
04/04Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 milli..
CI
03/04Wuhan Healthgen Biotechnology Corp. announced that it expects to receive CNY 464.999997..
CI
01/23Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 mi..
CI
2021JL Mag Rare-Earth Testing Waters for $200 Million Hong Kong IPO
MT
2021Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
2021Hangzhou Neoantigen Biotechnology co., LTD. announced that it has received $3.1 million..
CI
2021Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
2021MARKET CHATTER : JL Mag Rare-Earth Files for $200 Million Hong Kong IPO; Shares Jump 3%
MT
More news
News in other languages on BETTA PHARMACEUTICALS CO., LTD.
05/23Betta Pharmaceuticals Co., Ltd. annonce un dividende en espèces pour 2021, payable le 3..
05/04EyePoint Pharmaceuticals accorde à Betta Pharmaceuticals les droits de commercialisatio..
04/29Betta Pharmaceuticals Co., Ltd. approuve le plan de distribution des bénéfices pour 202..
04/26Betta Pharmaceuticals Co., Ltd. annonce ses résultats pour le premier trimestre clos le..
04/07Betta Pharmaceuticals Co., Ltd. propose un dividende final en espèces pour 2021
More news
Chart BETTA PHARMACEUTICALS CO., LTD.
Duration : Period :
Betta Pharmaceuticals Co., Ltd. Technical Analysis Chart | 300558 | CNE100002DD9 | MarketScreener
Technical analysis trends BETTA PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 44,18 CNY
Average target price 85,80 CNY
Spread / Average Target 94,2%
EPS Revisions
Managers and Directors
Lie Ming Ding Chairman, Co-Chief Executive Officer & GM
Jia Tong Co-Chief Executive Officer
Jian Xun Fan Chief Financial Officer
Yang Nan Zhang Chairman-Supervisory Board
Jiang Wan Executive Director & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BETTA PHARMACEUTICALS CO., LTD.-44.66%2 739
MERCK KGAA-21.50%83 006
KYOWA KIRIN CO. LTD.-12.92%11 543
SK BIOPHARMACEUTICALS CO., LTD.-9.77%5 492
YUHAN CORPORATION-3.70%3 252
INDIVIOR PLC25.37%2 855